Arkansas Children's Hospital Research Institute (ACHRI)

A Randomized, Multicenter, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of a Combination Product Containing Sumatriptan and Naproxen Sodium for the Acute Treatment of Migraine in Adolescents

Indications:
Head Aches - Migraines

Study Description:
This study will evaluate the effectiveness of a range of doses of a combination product containing sumatriptan and naproxen sodium for the acute treatment of migraines in adolescents age 12-17 years old.

The study will last up to 25 weeks and includes up to 3 visits during the 25 weeks for eligible subjects.

For more information, contact Robin Gibson, RN at 501-364-1542.

Eligibility Requirements:
1) 12 to 17 years old 2) weigh at least 74 pounds 3) have a history of 2 to 8 migraines per month 4) otherwise be in general good health Other inclusion/exclusion criteria must be met prior to enrollment. The Study Coordinator can provide more information on the criteria.

 

Request Information for This Trial

 

 

Joint Notice of Privacy Practices | Terms & Conditions of Use | Report Concerns About Patient Care & Safety | Site Index

About ACH | Your Visit to ACH | Community Outreach Programs
Medical Services | Career Opportunities | Volunteer Opportunities
ACH Foundation | Press Room | Resources | Research | Kids Only | Contact Us